Lv1
74 积分 2024-02-01 加入
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
1个月前
已完结
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
1个月前
已完结
Envafolimab-Associated Toxic Epidermal Necrolysis
1个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
2个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
6个月前
已完结
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
6个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
6个月前
已完结
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
6个月前
已完结
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma
7个月前
已完结
皖公网安备34019202002308
